Recombinant human erythropoietin plus methylprednisolone versus methylprednisolone in treatment of acute spinal cord injury:protocol for a systematic review and meta-analysis

Department of orthopedics, Chengdu Second People's Hospital, Chengdu, China. Department of orthopedics, West China Hospital of Sichuan University, Chengdu, China. Department of Ultrasound, Sichuan University West China Hospital, Chengdu, Sichuan, China zhoujiaojiao@wchscu.cn. Chinese Evidence-Based Medicine Center, Sichuan University West China Hospital, Chengdu, Sichuan, China.

BMJ open. 2022;12(12):e056689
Full text from:
Abstract
INTRODUCTION Recent studies in animal models indicate that recombinant human erythropoietin (rHuEPO) is very effective in enhancing neurological recovery after spinal cord injury (SCI). We described a protocol aimed at evaluating the efficacy of rHuEPO plus methylprednisolone (MP) compared with MP alone in improving neurological function of patients with SCI in randomised controlled trials (RCTs). METHODS AND ANALYSIS This study aims to explore the effect of rHuEPO combined with MP on neurological function in patients with SCI through a meta-analysis. To this end, the authors will search eight research databases for data retrieval: MEDLINE, China National Knowledge Infrastructure, Wan Fang, China Biology Medicine dis, Web of Science, PubMed, Cochrane and Embase for RCTs on SCI in any language. The primary outcome will be the American Spinal Injury Association score at the time of follow-up. The secondary outcomes will be the WHOQOL-100 instrument score, neurophysiological state and related factors. Two authors will independently search literature records, scan titles, abstracts and full texts, collect data, and assess materials for risk of bias. Stata V.14.0 will be used for statistical analysis. ETHICS AND DISSEMINATION This research is exempt from ethics approval because the work is carried out on published documents. We will disseminate this protocol in scientific conferences and a peer-reviewed journal. PROSPERO REGISTRATION NUMBER CRD42021260688.
Study details
Study Design : Systematic Review
Language : eng
Credits : Bibliographic data from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine